Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$4.68 - $9.26 $14,040 - $27,780
3,000 Added 3.46%
89,689 $448,000
Q1 2023

May 10, 2023

SELL
$7.53 - $10.95 $77,559 - $112,784
-10,300 Reduced 10.62%
86,689 $819,000
Q4 2022

Feb 08, 2023

BUY
$9.44 - $13.09 $915,576 - $1.27 Million
96,989 New
96,989 $967,000
Q2 2022

Aug 09, 2022

SELL
$6.99 - $10.0 $652,167 - $933,000
-93,300 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$7.26 - $10.7 $59,532 - $87,740
8,200 Added 9.64%
93,300 $741,000
Q2 2021

Aug 06, 2021

BUY
$17.8 - $23.5 $46,280 - $61,100
2,600 Added 3.15%
85,100 $1.84 Million
Q1 2021

May 07, 2021

BUY
$17.18 - $22.6 $24,052 - $31,640
1,400 Added 1.73%
82,500 $1.67 Million
Q2 2020

Aug 05, 2020

BUY
$7.35 - $10.81 $89,670 - $131,882
12,200 Added 17.71%
81,100 $749,000
Q1 2020

May 08, 2020

BUY
$8.38 - $17.34 $10,894 - $22,542
1,300 Added 1.92%
68,900 $717,000
Q4 2019

Feb 06, 2020

BUY
$11.18 - $18.6 $26,832 - $44,640
2,400 Added 3.68%
67,600 $1.21 Million
Q2 2019

Aug 02, 2019

BUY
$18.5 - $25.47 $98,050 - $134,991
5,300 Added 8.85%
65,200 $1.29 Million
Q1 2019

May 10, 2019

BUY
$14.62 - $22.13 $33,626 - $50,899
2,300 Added 3.99%
59,900 $1.26 Million
Q4 2018

Feb 13, 2019

BUY
$17.09 - $38.25 $17,090 - $38,250
1,000 Added 1.77%
57,600 $1.18 Million
Q3 2018

Nov 08, 2018

BUY
$34.05 - $55.9 $149,820 - $245,960
4,400 Added 8.43%
56,600 $2.09 Million
Q2 2018

Aug 09, 2018

BUY
$36.15 - $52.5 $101,220 - $147,000
2,800 Added 5.67%
52,200 $2.62 Million
Q1 2018

May 04, 2018

BUY
$24.4 - $40.25 $26,840 - $44,275
1,100 Added 2.28%
49,400 $1.8 Million
Q4 2017

Feb 07, 2018

BUY
$18.5 - $28.6 $893,550 - $1.38 Million
48,300
48,300 $1.37 Million

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $763M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.